Ocuphire Pharma Inc OCUP

NAS: OCUP | ISIN: US67577R1023 14/11/2024

1,060 USD (-2,75%)

(-2,75%) 14/11/2024

Grafiek Ocuphire Pharma Inc

Grafiek Ocuphire Pharma Inc

1 dag1d -2,75%
1 week1w -5,36%
1 maand1m -15,20%
3 maanden3m -14,52%
6 maanden6m -38,73%
1 jaar1j -66,35%
5 jaar5j -39,43%

Ocuphire Pharma Inc in het nieuws

Toon enkel gratis nieuws

27 september 2023 · Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents · Persbericht

15 maart 2021 · Ocuphire Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpoint · Persbericht

10 maart 2021 · Ocuphire Announces Financial Results for the Full Year 2020 and Provides Corporate Update · Persbericht

5 maart 2021 · Ocuphire Announces Publication of MIRA-1 Phase 2b Results in Optometry and Visual Science Demonstrating Reduction of Pharmacologically Induced Mydriasis by Nyxol® · Persbericht

18 februari 2021 · Ocuphire Initiates Enrollment in VEGA-1 Phase 2 Trial Investigating Nyxol in Presbyopia · Persbericht

11 februari 2021 · Ocuphire to Participate in the 2021 BIO CEO & Investor Conference and Cantor Fitzgerald’s Panel on Eyeing Key Events in the Ophthalmology Space in 2021 · Persbericht

20 januari 2021 · Ocuphire Announces Publication of ORION-1 Phase 2 Results for Nyxol in Clinical Ophthalmology and Presentation at the January OIS Presbyopia Innovation Showcase · Persbericht

Profiel Ocuphire Pharma Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.rexahn.com

Hoofdzetel: Rockville, Maryland Verenigde Staten

CEO: Douglas Swirsky

Werknemers: 14

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe